Sage Journals: Discover world-class research

Abstract

Background

Drug treatment of refractory irritable bowel syndrome (IBS) is not satisfactory at present. This study investigated the clinical effects of ebastine combined with low-dose antidepressants on refractory IBS.

Methods

A total of 105 patients with refractory refractory IBS were randomly assigned to two different treatment groups after signing informed consent. And they didn't know about the treatment group they were in. They were administered with ebastine (Group A) or ebastine combined with flupentixol and melitracen (Group B) for 4 weeks. Drug efficacy was evaluated using scales before and after treatment. In addition, serum D-lactate (D-LAC) and human intestinal fatty acid binding protein (I-FABP) level were measured to assess intestinal permeability.

Results

Significant improvements were observed in IBS Quality of Life (IBS-QOL) score, IBS Symptom Severity Scale (IBS-SSS) score, and total sleep quality score. Patients in Group A showed no improvements in anxiety (44.83 ± 9.62 vs. 43.92 ± 10.43, P = 0.415) and depression (39.08 ± 9.34 vs. 38.75 ± 9.35, P = 0.674) compared with the baseline level, while those in Group B improved significantly on anxiety (52.12 ± 8.19 vs. 39.28 ± 9.88) and depression (47.64 ± 9.53 vs. 38.24 ± 9.41) status. After treatment, the serum levels of D-LAC and I-FABP were significantly lower in Group B than in Group A.

Conclusion

Refractory IBS patients showed certain psychological abnormalities. Ebastine combined with antidepressants exhibited more obvious benefits on QOL, sleep quality, and SSS, with significant improvements in psychological status and intestinal permeability in refractory IBS patients.

Keywords

irritable bowel syndrome psychological factor quality of life treatment

Get full access to this article

View all access options for this article.

References

Staudacher

Black

Teasdale

, et al. Irritable bowel syndrome and mental health comorbidity - approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol 2023; 20: 582–596.

Dothel

Barbaro

Di Vito

, et al. New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics. J Gastroenterol 2023; 58: 605–621.

Yanping

Gao

Cheng

, et al. The interaction between obesity and visceral hypersensitivity. J Gastroenterol Hepatol 2023; 38: 370–377.

Shiha

Aziz

. Review article: physical and psychological comorbidities associated with irritable bowel syndrome. Aliment Pharmacol Ther 2021; 54: S12–S23.

Pan

Huang

, et al. Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis. BMC Psychiatry 2025; 25: 64.

Basiji

Sendani

Ghavami

, et al. The critical role of gut-brain axis microbiome in mental disorders. Metab Brain Dis 2023; 38: 2547–2561.

Begré

Fox

Jordi

SBU

, et al. Functional disorders in chronic inflammatory bowel disease: the gut-brain axis. Inn Med (Heidelb) 2025; 66: 181–189.

Khasawneh

Black

Ford

. Efficacy of drugs acting on histamine 1 receptors in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology 2024; 167: 400–401.e3.

Liu

Nakamura

Kawashima

. New role of the serotonin as a biomarker of gut-brain interaction. Life (Basel) 2024; 14: 1–2, 11–12.

10.

Ford

. Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks? Gut 2024; 73: 393–394.

11.

Hojo

Nagahara

. Current perspectives on irritable bowel syndrome: a narrative review. J Int Med Res 2022; 50: 3000605221126370.

12.

Weerts

Masclee

AAM

Witteman

BJM

, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020; 158: 123–136.

13.

Oka

Parr

Barberio

, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908–917.

14.

Dunstan

Scott

. Norms for Zung's Self-rating Anxiety Scale. BMC Psychiatry 2020; 20: 90.

15.

Dunstan

Scott

. Clarification of the cut-off score for Zung's self-rating depression scale. BMC Psychiatry 2019; 19: 177.

16.

Camacho-Díaz

Arenas-Ocampo

Osorio-Díaz

, et al. The effects of agave fructans in a functional food consumed by patients with irritable bowel syndrome with constipation: a randomized, double-blind, placebo-controlled trial. Nutrients 2023; 15: 3526.

17.

Zitser

Allen

Falgàs

, et al. Pittsburgh Sleep Quality Index (PSQI) responses are modulated by total sleep time and wake after sleep onset in healthy older adults. PLoS One 2022; 17: e0270095.

18.

Skrzydło-Radomańska

Prozorow-Król

Cichoż-Lach

, et al. The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study. Nutrients 2021; 13: 756.

19.

Shaikh

Sun

Canakis

, et al. Irritable bowel syndrome and the gut microbiome: a comprehensive review. J Clin Med 2023; 12: 2558.

20.

Huang

Wang

, et al. Irritable bowel syndrome: epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol. 2023; 29: 4120–4135.

21.

Shimbori

De Palma

Baerg

, et al. Gut bacteria interact directly with colonic mast cells in a humanized mouse model of IBS. Gut Microbes 2022; 14: 2105095.

22.

Chen

Chaudhary

, et al. Sleep dysfunction mediates the relationship between hypothalamic-insula connectivity and anxiety-depression symptom severity bidirectionally in young adults. NeuroImage 2023; 279: 120340.

23.

Hasler

Grabauskas

Singh

, et al. Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome. Neurogastroenterol Motil. 2022; 34: e14339.

24.

Grabauskas

Gao

, et al. Prostaglandin E(2), produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice. Gastroenterology 2020; 158: 2195–2207.e6.

25.

Wouters

Balemans

Van Wanrooy

, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology 2016; 150: 875–887.e9.

26.

Balfour

Iyaniwura

. An investigation of amphetamine-induced release of 5-HT from rat hippocampal slices. Eur J Pharmacol 1985; 109: 395–399.

27.

Jorgensen

Juul

Siddiqui

, et al. Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Syst Rev 2021; 10: 227.

28.

Guo

, et al. A preliminary study of resting-state fMRI in patients with diarrhea-type irritable bowel syndrome after pinaverium bromide combined treatment with flupentixol-melitracen. Zhonghua Yi Xue Za Zhi 2019; 99: 3266–3272.

29.

Qin

Yang

, et al. Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e14064.

30.

Carrasco

Van de Kar

. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003; 463: 235–272.

31.

Ning

Wang

Xuan

, et al. Identification and investigation of depression-related molecular subtypes in inflammatory bowel disease and the anti-inflammatory mechanisms of paroxetine. Front Immunol 2023; 14: 1145070.

32.

Kellow

Gill

Wingate

. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome. Gastroenterology 1990; 98: 1208–1218.

33.

Tang

Zhu

, et al. Gut dysbiosis and intestinal barrier dysfunction promotes IgA nephropathy by increasing the production of Gd-IgA1. Front Med (Lausanne) 2022; 9: 944027.

34.

Vollrath

Klingebiel

Bläsius

, et al. I-FABP as a potential marker for intestinal barrier loss in porcine polytrauma. J Clin Med. 2022; 11: 4599.

35.

Habes

QLM

Kant

Beunders

, et al. Relationships between systemic inflammation, intestinal damage and postoperative organ dysfunction in adults undergoing low-risk cardiac surgery. Heart Lung Circ. 2023; 32: 395–404.

36.

Efremova

Maslennikov

Medvedev

, et al. Gut Microbiota and biomarkers of intestinal barrier damage in cirrhosis. Microorganisms 2024; 12: 463.

37.

Diao

Guo

, et al. Causal association between psycho-psychological factors, such as stress, anxiety, depression, and irritable bowel syndrome: Mendelian randomization. Medicine (Baltimore) 2023; 102: e34802.

38.

Tao

, et al. Early life stress induces irritable bowel syndrome from childhood to adulthood in mice. Front Microbiol 2023; 14: 1255525.

39.

Yuan

Wang

Huang

, et al. Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships. Gut Microbes 2023; 15: 2263209.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.07 MB

0.00 MB

Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial

Abstract

Background

Methods

Results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material